Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

Figure 1

Kaplan Meier curve for progression free survival of metastatic colorectal cancer patients treated by FOLFIRI3-bevacizumab in the first line setting. The probability of progression free survival is reported in the 21 patients treated with FOLFIRI3-bevacizumab who underwent a surgery of their metastases and in the 40 patients with unresectable disease.

Back to article page